Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Findings of the present study provide a molecular
2023-08-11

Findings of the present study provide a molecular mechanism for the elevated ASK1 expression in obesity and how it may be functionally linked to whole-body insulin resistance. The role our findings assign to increased E2F1 in upregulating ASK1 parallels the capacity of this transcription factor to r
-
br Acknowledgments br Introduction Angiotensin II AngII
2023-08-11

Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the
-
Other reports however have indicated
2023-08-11

Other reports, however, have indicated that all components of RAS are produced within the central nervous system (CNS) (Saavedra, 2005). Thus, AGTR1 and AGTR2 in circumventricular organs and in cerebrovascular endothelial cells may respond to circulating ANG2 of peripheral origin, whereas neural rec
-
For patients who have taken advantage of the anti TKIs
2023-08-11

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
CHIR-090 In our study the expression levels of adiponectin a
2023-08-11

In our study, the expression levels of adiponectin and its receptors in the uteri, conceptuses, and throphoblasts were determined by the stage of early pregnancy. Therefore, it could be hypothesized that the adiponectin system is regulated by the local hormonal milieu. Hormonal regulation in the ute
-
The assay performance was estimated using
2023-08-11

The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicati
-
Multiple ASD susceptibility genes converge on cellular pathw
2023-08-11

Multiple ASD susceptibility genes converge on cellular pathways that intersect at the postsynaptic site of glutamatergic synapses (Bourgeron, 2015; Peca & Feng, 2012), the development and maturation of synaptic contacts (Gilman et al., 2011) or synaptic transmission (Li et al., 2014). The majority o
-
The first natural product described as LO inhibitor was the
2023-08-11

The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic Stattic from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time before mPGES-1 was
-
Although experiments on animals and cells indicate that anti
2023-08-11

Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
pyrazine uses The introduction of a pyrazole moiety into any
2023-08-11

The introduction of a pyrazole moiety into any position of the sterane core by cross-coupling reactions [13] or by Knorr construction from a CCC bis-electrophilic sterane precursor and an N,N binucleophile building block [17], [19] may serve as an example. Very few reports are to be found, however,
-
br Patients and Methods br
2023-08-11

Patients and Methods Results Discussion Gjerdrum et al showed that Axl 6-Aminonicotinamide is required to maintain the mesenchymal-like invasiveness of metastatic breast carcinoma cells, but Axl knockdown has no effect on the cell proliferation of MDA-MB-231 cells. Mackiewicz et al also sh
-
zotarolimus br Acknowledgments br Introduction Cancer is the
2023-08-11

Acknowledgments Introduction Cancer is the leading cause of mortality in the United States for those between the ages of 40–79 years, surpassing heart diseases by more than 100,000 deaths [1]. The cause of most cancer subtypes remains idiopathic and may arise out of ‘bad luck’ among otherwise
-
PF also a dual Aurora A and
2023-08-11

PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly GSK-LSD1 hydrochloride for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the
-
Aurora A overexpression is also
2023-08-11

Aurora-A overexpression is also related to the activation of NF-κB, a potent anti-apoptotic effector that may play a role in preventing apoptosis in cancer 265 3 [18]. These data show that we are still at the beginning of unraveling the complex mechanism by which these gene products and proteins i
-
At the outset of targeting the two Gln side chain
2023-08-10

At the outset of targeting the two Gln756 side-chain rotamers, it was unclear which rotational isomer would lead to more potent ASK1 inhibitors. While such a preference might have been anticipated, the cohort of ASK1 inhibitors in Table 3 did not provide any guidance regarding which of the Gln756 am
16529 records 315/1102 page Previous Next First page 上5页 311312313314315 下5页 Last page